These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29101115)

  • 1. Efforts to Develop KRAS Inhibitors.
    Holderfield M
    Cold Spring Harb Perspect Med; 2018 Jul; 8(7):. PubMed ID: 29101115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
    Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C
    J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.
    Bery N; Legg S; Debreczeni J; Breed J; Embrey K; Stubbs C; Kolasinska-Zwierz P; Barrett N; Marwood R; Watson J; Tart J; Overman R; Miller A; Phillips C; Minter R; Rabbitts TH
    Nat Commun; 2019 Jun; 10(1):2607. PubMed ID: 31197133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
    Hyun S; Shin D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
    Yang A; Li M; Fang M
    Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
    Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
    J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
    Ostrem JM; Shokat KM
    Nat Rev Drug Discov; 2016 Nov; 15(11):771-785. PubMed ID: 27469033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in targeting RAS with small molecule drugs.
    McCormick F
    Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
    Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
    J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
    Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
    Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
    Salgia R; Pharaon R; Mambetsariev I; Nam A; Sattler M
    Cell Rep Med; 2021 Jan; 2(1):100186. PubMed ID: 33521700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting KRAS in cancer.
    Singhal A; Li BT; O'Reilly EM
    Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRASG12C inhibitor: combing for combination.
    Chakraborty A
    Biochem Soc Trans; 2020 Dec; 48(6):2691-2701. PubMed ID: 33242077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.